(Press-News.org) Contact information: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Vemurafenib: Result unchanged despite new data
Results from later analysis dates uncertain because patients switched between treatments
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment of adults with a certain type of advanced melanoma. The reason for this was that the Federal Joint Committee (G-BA) had limited its decision on the first assessment to one year. This obliged the drug manufacturer to submit a second dossier.
This dossier contained additional and more recent data, but did not provide any new findings. IQWiG therefore still considers there to be an indication of a considerable added benefit of vemurafenib.
Longer survival, but also major side effects
The drug approved since February 2012 can be an option for adults whose melanoma cannot be removed by surgery or has formed secondaries (metastases) and in whose cancer a change (mutation) has occurred in a certain gene (BRAF-V600). G-BA had specified the drug dacarbazine as the appropriate comparator therapy.
In its first AMNOG assessment in June 2012, the Institute concluded that vemurafenib had major advantages in overall survival, but also major disadvantages in the form of side effects. Overall, this resulted in an indication of a considerable added benefit.
Treatments mixed during the course of the study
The manufacturer used the approval study again in its second dossier, and presented additional results from later analysis dates (data cut-offs). However, because of the special design of this study, the risk of bias of the results increased with each data cut-off.
In the first year of the study, patients in whom the disease progressed could be treated with further anti-cancer treatments. They could not switch from dacarbazine to vemurafenib, however. The analysis after this first year was therefore informative for the comparison of vemurafenib and dacarbazine. After this analysis, it was possible to switch from dacarbazine to vemurafenib, which made the results for the comparison of the two treatment options increasingly uncertain. This is the reason why IQWiG did not draw any new conclusions from the later analyses now provided.
Historical comparison is unsuitable
In the second dossier, the manufacturer also added a so-called "historical comparison": Firstly, it compared the survival rates under dacarbazine from other studies with the survival rates under dacarbazine from the approval study. It then related the results of this comparison to the survival rates of vemurafenib (approval study). With regards to the added benefit of vemurafenib, this did not result in any new findings beyond the ones from the approval study. At the most, the historical comparison allows the conclusion that patients in the approval study possibly had a better prognosis than patients in older studies.
Hence the new manufacturer dossier did not contain any new data that would be suitable for describing the added benefit of vemurafenib. Hence the result of the first assessment remains valid.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on vemurafenib.
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of vemurafenib.
### END
Vemurafenib: Result unchanged despite new data
Results from later analysis dates uncertain because patients switched between treatments
2013-12-18
ELSE PRESS RELEASES FROM THIS DATE:
Toward lowering titanium's cost and environmental footprint for lightweight products
2013-12-18
Toward lowering titanium's cost and environmental footprint for lightweight products
A novel method for extracting titanium, a metal highly valued for its light weight, high strength, corrosion resistance and biocompatibility, could lower its cost and make ...
44 percent of adults worry e-cigarettes will encourage kids to start smoking tobacco
2013-12-18
44 percent of adults worry e-cigarettes will encourage kids to start smoking tobacco
Almost half of parents concerned their child will try e-cigarettes; support high for prohibiting sale to kids, says U-M National Poll on Children's Health
ANN ARBOR, Mich. ...
Suggested ban on trans fat begs the question: Are substitutes any healthier?
2013-12-18
Suggested ban on trans fat begs the question: Are substitutes any healthier?
Health advocates cheered last month's U.S. Food and Drug Administration (FDA) proposal to ban partially hydrogenated oils — which contain trans fats that increase the risk of heart ...
Toward lowering titanium's cost and environment
2013-12-18
Toward lowering titanium's cost and environment
In the quest to shrink motors so they can maneuver in tiny spaces like inside and between human cells, scientists have taken inspiration from millions of years of plant evolution and incorporated, for the first ...
Leading health care executives optimistic about health care reform, Penn survey shows
2013-12-18
Leading health care executives optimistic about health care reform, Penn survey shows
Views differ sharply from general public, politicians, and commentators
Philadelphia - Nearly two-thirds (65 percent) of the nation's leading health ...
Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation
2013-12-18
Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation
Putnam Valley, NY. (Dec. 18, 2013) – Hepatocyte (liver cell) transplantation is becoming an accepted therapy for acute liver failure, either for ...
Preferable treatment for MS found in allogenic bone marrow stem cells
2013-12-18
Preferable treatment for MS found in allogenic bone marrow stem cells
MSCs isolated from MS patients have decreased suppressive function compared to those of healthy counterparts
Putnam Valley, NY. (Dec. 18, 2013) – Multiple sclerosis ...
New actors in the Arctic ecosystem
2013-12-18
New actors in the Arctic ecosystem
Atlantic amphipods are now reproducing in Arctic waters
Biologists from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) have for the first time ...
'Macrocells' influence corrosion rate of submerged marine concrete structures
2013-12-18
'Macrocells' influence corrosion rate of submerged marine concrete structures
Using numerical modeling, an Italian research team has discovered the role 'macrocells' play in the corrosion of hollow submerged marine concrete structures such as tunnels and parking structures.
In ...
Oil- and metal-munching microbes dominate deep sandstone formations
2013-12-18
Oil- and metal-munching microbes dominate deep sandstone formations
Findings useful to hydrocarbon extraction and carbon sequestration efforts
CHAMPAIGN, Ill. — Halomonas are a hardy breed of bacteria. They can withstand heat, high salinity, low oxygen, ...
LAST 30 PRESS RELEASES:
‘Molecular shield’ placed in the nose may soon treat common hay fever trigger
Beetles under climate stress lay larger male eggs: Wolbachia infection drives adaptive reproduction strategy in response to rising temperature and CO₂
Groundbreaking quantum study puts wave-particle duality to work
Weekly injection could be life changing for Parkinson’s patients
Toxic metals linked to impaired growth in infants in Guatemala
Being consistently physically active in adulthood linked to 30–40% lower risk of death
Nerve pain drug gabapentin linked to increased dementia, cognitive impairment risks
Children’s social care involvement common to nearly third of UK mums who died during perinatal period
‘Support, not judgement’: Study explores links between children’s social care involvement and maternal deaths
Ethnic minority and poorer children more likely to die in intensive care
Major progress in fertility preservation after treatment for cancer of the lymphatic system
Fewer complications after additional ultrasound in pregnant women who feel less fetal movement
Environmental impact of common pesticides seriously underestimated
The Milky Way could be teeming with more satellite galaxies than previously thought
New study reveals surprising reproductive secrets of a cricket-hunting parasitoid fly
Media Tip Sheet: Symposia at ESA2025
NSF CAREER Award will power UVA engineer’s research to improve drug purification
Tiny parasitoid flies show how early-life competition shapes adult success
New coating for glass promises energy-saving windows
Green spaces boost children’s cognitive skills and strengthen family well-being
Ancient trees dying faster than expected in Eastern Oregon
Study findings help hone precision of proven CVD risk tool
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Introducing BioEmu: A generative AI Model that enables high-speed and accurate prediction of protein structural ensembles
Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans
New research shows how tropical plants manage rival insect tenants by giving them separate ‘flats’
Condo-style living helps keep the peace inside these ant plants
Climate change action could dramatically limit rising UK heatwave deaths
Annual heat-related deaths projected to increase significantly due to climate and population change
Researchers discover new way cells protect themselves from damage
[Press-News.org] Vemurafenib: Result unchanged despite new dataResults from later analysis dates uncertain because patients switched between treatments